Glucosylceramide Synthase Inhibitor [EPC]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Glucosylceramide Synthase Inhibitor [EPC] includes 2 drugs with a combined 2,127 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
2,127
Combined Reports
All Glucosylceramide Synthase Inhibitor [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| ELIGLUSTAT | Cerdelga | 1,368 | 18 | 173 | 1.3% |
| MIGLUSTAT | MIGLUSTAT | 759 | 219 | 307 | 28.9% |
Common Side Effects in Glucosylceramide Synthase Inhibitor [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Weight decreased | 163 | 7 |
| Diarrhoea | 145 | 10 |
| Death | 143 | 143 |
| Weight increased | 137 | 0 |
| Seizure | 113 | 5 |
| Product dose omission in error | 110 | 0 |
| Product dose omission issue | 87 | 0 |
| Fatigue | 86 | 2 |
| Pneumonia | 83 | 20 |
| Off label use | 82 | 38 |